225 FRANKLIN STREET, BOSTON, MA
Market cap: $18.0M (12/12/2024)
Price: $13.60
Palvella Therapeutics Reports Positive Phase 2 Results for QTORIN™ in Treating Rare Genetic Disease
Financial Results, Reg. FD
Palvella Therapeutics Unveils QTORIN™ Pitavastatin for DSAP Treatment
Palvella Therapeutics Expands QTORIN™ Development for Rare Lymphatic Disease
1 First - in - disease therapies for patients with rare genetic skin diseases
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Shareholder votes
Reports First Quarter 2025 Financial Results and Provides Corporate Update
Q3
Q2
Q1
FY 2024
FY 2023 amended
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Prospectus Filed Pursuant to Rule 425
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report